Related Experiment Videos
MCI-186: further histochemical and biochemical evidence of neuroprotection
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto Western Hospital, Canada. taiwu@hotmail.com
Abstract:
The bioactivity of 3-methyl-1-phenyl-pyrazolin-5-one (MCI-186) was examined based on histochemical changes in drastic global ischemic rat brains. Rats with mean arterial blood pressure reduction were subjected to 60 min cerebral ischemia/80 min reperfusion. Infusion of MCI-186 at 3.0 mg/Kg reduced brain infarction from 21 +/- 4% (saline control, n= 15) to 11 +/- 3% (n=16, p<0.05). By comparison, infusion of up to 20 mg/Kg propyl galalate (PG)--a well documented antioxidant--produced an infarct percentage of 14 +/- 5% (n=8), close to the saline control. Biochemically, the neuroprotective effect of MCI-186 was demonstrated by diminishing the release of creatine kinase (CK) in serum from 3363 +/- 608 U/L (n=14) in saline control to 1989 +/- 293 U/L (n= 15) in MCI group (p<0.05), while PG did not lower the activity of CK significantly. MCI-186 behaves as a free radical scavenger by suppressing the formation of superoxide anion in xanthine oxidase (XO)-hypoxanthine (HP) system (p<0.05). Our data supported our contention that MCI-186 has potent anti-stroke effect with antioxidant activities.
Insights
3-methyl-1-phenyl-pyrazolin-5-one (MCI-186) significantly reduced brain infarction in rats by acting as a potent antioxidant and free radical scavenger. This neuroprotective effect suggests MCI-186 has significant anti-stroke potential.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Global cerebral ischemia leads to significant brain damage.
- 3-methyl-1-phenyl-pyrazolin-5-one (MCI-186) is a compound with potential therapeutic properties.
- Antioxidants are crucial in mitigating ischemic brain injury.
Purpose of the Study:
- To evaluate the neuroprotective effects of MCI-186 in a rat model of global cerebral ischemia.
- To investigate the antioxidant and free radical scavenging activities of MCI-186.
- To compare the efficacy of MCI-186 with a known antioxidant, propyl gallate (PG).
Main Methods:
- Global cerebral ischemia was induced in rats by reducing mean arterial blood pressure.
- Rats were subjected to 60 minutes of ischemia followed by 80 minutes of reperfusion.
- Histochemical analysis was used to assess brain infarction, and biochemical assays measured creatine kinase (CK) levels and superoxide anion formation.
Main Results:
- MCI-186 infusion (3.0 mg/Kg) reduced brain infarction by approximately 48% compared to saline control (p<0.05).
- Propyl gallate (PG) showed minimal reduction in brain infarction, similar to the saline control.
- MCI-186 significantly decreased serum creatine kinase (CK) levels and suppressed superoxide anion formation in the xanthine oxidase-hypoxanthine system (p<0.05).
Conclusions:
- MCI-186 demonstrates potent anti-stroke effects by reducing brain infarction and neurochemical markers of injury.
- The compound exhibits significant antioxidant and free radical scavenging activities.
- MCI-186 holds promise as a therapeutic agent for ischemic stroke treatment.